Boehringer Ingelheim has presented data at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting showing that the Spiriva Respimat tiotropium bromide soft mist inhaler improves lung function and reduces exacerbations when added to other treatments for all allergic asthma subtypes. The addition of Spiriva Respimat also improved asthma symptoms as measured by the ACQ-7 asthma control questionnaire.
The data come from 2 PrimoTinA-asthma and 2 MezzoTinA-asthma trials, part of the UniTinA-asthma Phase 3 clinical trial program.
The FDA approved Spiriva Respimat for the treatment of asthma in the US in September 2015, and the product has been available in the US for that indication since February 2016.
BI Pharmaceuticals VP of Clinical Development & Medical Affairs, Respiratory, Danny McBryan commented, “Boehringer Ingelheim is committed to pursuing scientific research to help address unmet needs and improve patient care for people living with asthma. These data further demonstrate the benefits of Spiriva Respimat for the broad range of asthma patients studied who continued to experience symptoms despite taking other maintenance therapies, regardless of allergy subtype.”
Read the Boehringer Ingelheim press release.
